Glenmark gets USFDA nod for contraceptive tablets

PTI New Delhi | Updated on January 20, 2018 Published on February 24, 2016


Glenmark Pharmaceuticals has received the final nod from the US health regulator for generic oral contraceptive norgestimate ethinyl estradiol tablets.

In a BSE filing, the company said Glenmark Pharmaceuticals USA has been granted final approval by the US Food & Drug Administration (USFDA) for “norgestimate and ethinyl estradiol tablets USP, 0.18 mg/0.025 mg, 0.215 mg/ 0.025 mg and 0.25 mg/0.025mg“.

Approval has been granted for the generic version of Ortho Tri-cyclen Lo tablets of Janssen Pharmaceuticals, Inc.

According to IMS Health sales data for the 12 months to December 2015, the Ortho Tri-cyclen Lo tablets achieved annual sales of around $503.9 million, Glenmark said.

The company’s current portfolio consists of 107 products authorised for distribution in the US marketplace and 62 Abbreviated New Drug Applications (ANDA) pending approval with the USFDA.

Shares of Glenmark Pharmaceuticals were today trading at Rs 738.40 apiece on BSE, down 1.32 per cent.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on February 24, 2016
This article is closed for comments.
Please Email the Editor